SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2013 / Cilt: 13 - Sayı: 3

Recent and future innovations in the treatment of heart failure

Kalp yetersizliği tedavisinde yeni açılımlar: Şimdi ve gelecek

Alper KEPEZ
Bülent MUTLU
Pages
266–274
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we will first focus on most recent treatment strategies that are recommended to be used in clinical practice and then try to mention novel strategies which are still being explored in preclinical studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Heart failure is still an important public health problem despite important advances regarding its treatment.
📊
Key Findings & Data:Several new treatment strategies are being investigated in order to contend with this disease.
💡
Conclusion & Impact:In this review, we will first focus on most recent treatment strategies that are recommended to be used in clinical practice and then try to mention novel strategies which are still being explored in preclinical studies.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Heart failure is still an important public health problem despite important advances regarding its treatment. Several new treatment strategies are being investigated in order to contend with this disease. Strategies proved to be safe and effective in clinical trials are being adapted to clinical practice. In this review, we will first focus on most recent treatment strategies that are recommended to be used in clinical practice and then try to mention novel strategies which are still being explored in preclinical studies.

Özet

Kalp yetersizliği, tedavide sağlanan tüm gelişmelere karşın halen önemli bir halk sağlığı problemi olmayı sürdürmektedir. Kalp yetersizliği ile daha etkin mücadele edilebilmesi için pek çok alanda yeni tedavi stratejileri geliştirilmekte ve test edilmektedir. Klinik çalışmalarda etkinliği kanıtlanan tedavi stratejileri ise klinik uygulamaya girmektedir. Bu yazıda kalp yetersizliği tedavisinde klinik uygulamaya eklenen son tedavi stratejileri özetlenecek ve halen araştırma safhasında olan klinik uygulamaya girmeye aday stratejilere göz atılacaktır.

🔖

Cite This Article

KEPEZ, A., MUTLU, B. (2022). Recent and future innovations in the treatment of heart failure. Anadolu Kardiyoloji Dergisi, Cilt: 13 - Sayı: 3, 266–274. https://ajindex.com/articles/436194

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Değertekin M, Erol C, Ergene O, Tokgözoğlu L, Aksoy M, Erol MK, ve ark. Türkiye’deki erişkin popülasyonda kalp yetersizliği prevelans ve prediktörleri: Heart failure prevalence and predictors in Turkey (HAPPY) çalışması. Turk Kardiyol Dern Ars 2012
  2. [CrossRef] 2. Sata Y, Krum H. The future of pharmacological therapy for heart failure. Circ J 2010
  3. [CrossRef] 3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008
  4. [CrossRef] 4. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012
  5. [CrossRef] 5. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust 2011
  6. Flynn KE, Piña IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009
  7. [CrossRef] 7. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009
  8. [CrossRef] 8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999
  9. [CrossRef] 9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N En